Nov 2026
Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
A novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib to selectively target LKB1-KRASG12C co-mutated NSCLC is investigated.
Xiang-Zheng Gao, Yi-Guan Chen, Liang-Liang Gao et al.
· Cancer Letters · 0 citations